BCL2 and acute myeloid leukemia: Thus, AML cells with miR-182 promoter hypermethylation have higher expression of BCL2 protein than those with miR-182 promoter hypomethylation, which partially sheds light on the consequence that AML patients with miR-182 promoter hypermethylation have better OS and LFS than those with hypomethylation.